Victory Capital Management Inc. Sells 260 Shares of Guardant Health, Inc. (NASDAQ:GH)

Victory Capital Management Inc. reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,578 shares of the company’s stock after selling 260 shares during the period. Victory Capital Management Inc.’s holdings in Guardant Health were worth $445,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of GH. SWS Partners increased its holdings in shares of Guardant Health by 44.3% in the 4th quarter. SWS Partners now owns 120,888 shares of the company’s stock worth $3,693,000 after buying an additional 37,126 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Guardant Health by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,016,533 shares of the company’s stock worth $31,055,000 after buying an additional 13,395 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter worth about $43,000. Jones Financial Companies Lllp increased its holdings in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after buying an additional 817 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd increased its holdings in shares of Guardant Health by 15.6% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 13,799 shares of the company’s stock worth $422,000 after buying an additional 1,863 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Performance

Shares of GH opened at $46.10 on Friday. The company has a 50 day moving average price of $43.85 and a 200-day moving average price of $33.57. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The stock has a market capitalization of $5.69 billion, a PE ratio of -12.95 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. Equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Upgrades and Downgrades

GH has been the subject of a number of recent analyst reports. Guggenheim reaffirmed a “buy” rating and set a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Raymond James reaffirmed an “outperform” rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Scotiabank lifted their price target on shares of Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 24th. Piper Sandler lifted their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Morgan Stanley lifted their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Twenty research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health presently has an average rating of “Buy” and an average price target of $48.40.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.